Physician profile
Frederick St Goar
NPI 1992710453
$2,208,673.71
in general payments reported to CMS, 2019-2025
22 companies · $5,742 in 2025
The $5,742 reported for 2025 was more than what 85% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $227 · 2021: $2.1M · 2022: $9,619 · 2023: $577 · 2024: $79K · 2025: $5,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $41K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Consulting Fee: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,500 · Food and Beverage: $2,355 · Royalty Or License: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $40,934.04 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,700.00 |
| Consulting Fee | $11,500.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,500.00 |
| Food and Beverage | $2,354.96 |
| Royalty Or License | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alydia Health | $2,063,507.07 | 2021 | |
| Abbott Laboratories | $86,581.44 | 2019-2025 | Mitraclip, Tendyne, Optis |
| Boston Scientific Corporation | $46,127.18 | 2021-2025 | Watchman Flx |
| Heartflow, INC. | $11,284.32 | 2019-2025 | Ffrct |
| Amgen INC. | $257.46 | 2019-2025 | Repatha |
| Medtronic, INC. | $253.91 | 2025 | Aurora Ev-Icd Mri Surescan, Omniasecure Mri Surescan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.19 | 2023-2025 | Jardiance |
| Pfizer INC. | $96.41 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $77.10 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $69.96 | 2021-2022 | |
| Medtronic Vascular, INC. | $66.43 | 2019 | |
| Merck Sharp & Dohme LLC | $54.21 | 2022-2023 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $23.09 | 2021 | |
| Bardy Diagnostics, INC. | $21.64 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.50 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $21.18 | 2021 | |
| Esperion Therapeutics, INC. | $19.66 | 2022 | |
| Cordis US Corp. | $18.96 | 2025 | Mynx Control Venous |
| E.R. Squibb & Sons, L.L.C. | $18.96 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.94 | 2023 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $18.07 | 2020 | |
| Octapharma USA, INC. | $17.03 | 2025 | Fibryga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$61,351,319.03 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick St Goar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.